BƯỚC ĐẦU ĐÁNH GIÁ HIỆU QUẢ ĐIỀU TRỊ CỦA DEXILANT 60MG TRÊN BỆNH NHÂN TRÀO NGƯỢC DẠ DÀY THỰC QUẢN CÓ TỔN THƯƠNG THỰC QUẢN SAU 4 TUẦN ĐIỀU TRỊ

Tùng Nguyễn Chí; Sơn Nguyễn Thái; Chương Nguyễn Văn

doi:10.59354/ydth175.2023.207

Keywords:

GERD, Gastroesophageal reflux disease

Abstract

Objective: to evaluate the effectiveness of Dexilant treatment in GERD patients with esophageal lesions.

Subjects and Methods: This is a descriptive prospective study. We conducted a study on 39 cases of GERD with esophageal lesions.

Results: After treatment, most of the clinical symptoms decreased significantly, p<0.05. The rate of reduction of clinical symptoms was statistically significant, p<0.05. With a reduction rate ranging from 88.3% - 100%, in which the typical symptoms of GERD are heartburn, regurgitation is the most effective with the rate of 97% and 100%, respectively. Change in frequency of GerdQ questions after treatment in a positive direction has statistical significance, p<0.05. The degree of reduction of clinical symptoms according to the GerdQ scale before and after treatment was statistically significant, p<0.0001. The rate of reduction in the level of GerdQ score 11-18 after treatment was the highest with 100%; level of 8-10 points, down 95.2%. There were 97.4% of the study subjects switched to the level of 3-7 points. - After treatment, the rate of healing of esophageal lesions decreased significantly, p<0.0001. 100% of patients with Grade B esophageal lesions recovered after treatment. 28/31 (90.3%) of patients with Grade A esophageal lesions were healed after treatment. Only 7.7% of patients have not yet healed. However, the extent of damage is also significantly reduced. No adverse effects of the drug have been reported.

Conclusion: Dexilant has a very good therapeutic effect on GERD patients with esophageal lesions.

References

Bộ môn nội tiêu hóa (2001) Bệnh trào ngược dạ dày thực quản, Bệnh học nội tiêu hóa, tr: 223-230

Bồ Kim Phượng (2012) Nghiên cứu ứng dụng bảng GerdQ trong chẩn đoán và theo dõi đáp ứng điều trị bệnh trào ngược dạ dày thực quản. Y học Tp.Hồ Chí Minh, 16(3): 44-48.

Kim J J (2018) Epidemiology of Gastroesophageal junction Adenocarcinoma in Korea. Journal of gastric cancer, 18(4): 328-338.

C Prakash Gyawali, Peter J Kahrilas, et al (2018) Modern diagnosis of GERD: The Lion Consensus. Gut, 67: 1351-1362.

Jone R, Junghard O, Dent J, et al (2009) Development of the GerdQ, a tool for the diagnosis and management of gastro-oesophageal reflux disease in primary care. Aliment Pharmacol Ther, 30(10): 1030-1038.

Skrzydlo-Radomanska B, Radwan P (2015) Dexlansoprazole – A new generation Proton pump inhibitor. Prz Gastroenterol, 10(4): 191-196

Hershcovici T, Jha L K, Fass R (2011) Dexlansoprazole MR: a review. Annals of medicine, 43(5): 366-374.

Lundell L R, Dent J, Bennett J R, et al (1999) Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut, 45(2): 172- 180.

Nguyễn Duy Thắng (2021) Đánh giá kết quả điều trị GERD bằng Dexilant 60mg trong 8 tuần và 4 tuần. Tạp chí khoa học tiêu hóa, 64: 3973-3980.

Trần Văn Thanh, Mai Thanh Bình, Hà Minh Trang và cộng sự (2021) Đánh giá hiệu quả điều trị Dexlansoprazole 60mg trên bệnh nhân trào ngược dạ dày thực quản mức độ nặng. Tạp chí Y dược lâm sàng 108, 16(4).

Surdea Blaga T, Negrutiu D E, Palage M, et al (2019) Food and Gastroesophageal reflux disease. Cur Med Chem, 26(19): 3497-3511.